23andMe weighing up sale of company

23andMe considers a sale as cash runs low
The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.
23andMe weighing up sale of the company as cash runs dry
Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering various directions for the company in addition to a sale,
23andMe considers sale amid financial struggles and leadership turmoil
By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a staggering 98% since going public.
23andMe weighs a sale as cash dwin­dles
Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs to raise more mon­ey to con­tin­ue …
23andMe running low on cash, considers sale, “strategic alternatives” by Special Committee
The latest unsurprising development in 23andMe’s story is the admission, by their new board of directors, that 23andMe now does not have enough cash to continue for the next 12 months. They are now considering the following strategic alternatives: a possible sale of the company,
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, including a potential sale, business combination, asset sales, restructuring, or other options, the company said in a statement.
23andMe says it's exploring alternatives, including a sale
Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, licensing of assets,
23andMe launches new genetic report on osteoporosis
Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
Nature8d
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...
Stocks to Watch: 23andMe, Manhattan Associates, Nextracker
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...